Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 300 (ZNF300) is a member of the KRAB (Krüppel-associated box) and C2H2-type zinc finger protein family, functioning primarily as a transcriptional repressor. ZNF300 binds to specific DNA sequences, modulating the transcription of multiple genes, likely through mechanisms involving both DNA methylation and histone modification. It is implicated in the regulation of cell differentiation—particularly in hematopoietic (blood) cells—and is dysregulated in several cancers, including leukemia and cervical cancer. However, ZNF300 is not currently established as a direct therapeutic target, nor are drugs or clinical biomarkers specifically associated with this protein[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 300 (ZNF300).